10.60
price down icon15.00%   -1.87
after-market After Hours: 10.70 0.10 +0.94%
loading
Uniqure N V stock is traded at $10.60, with a volume of 3.90M. It is down -15.00% in the last 24 hours and down -19.39% over the past month. uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$12.47
Open:
$11.34
24h Volume:
3.90M
Relative Volume:
3.72
Market Cap:
$575.38M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-1.6358
EPS:
-6.48
Net Cash Flow:
$-153.08M
1W Performance:
-28.23%
1M Performance:
-19.39%
6M Performance:
+115.01%
1Y Performance:
+103.85%
1-Day Range:
Value
$9.38
$11.40
1-Week Range:
Value
$9.38
$14.97
52-Week Range:
Value
$3.73
$19.18

Uniqure N V Stock (QURE) Company Profile

Name
Name
Uniqure N V
Name
Phone
1-339-970-7000
Name
Address
PAASHEUVELWEG 25A, AMSTERDAM
Name
Employee
209
Name
Twitter
@uniQure_NV
Name
Next Earnings Date
2024-07-30
Name
Latest SEC Filings
Name
QURE's Discussions on Twitter

Compare QURE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
QURE
Uniqure N V
10.60 575.38M 15.84M -308.48M -153.08M -6.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Uniqure N V Stock (QURE) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-10-24 Upgrade Raymond James Outperform → Strong Buy
Oct-10-24 Resumed Raymond James Outperform
Feb-29-24 Downgrade Goldman Buy → Neutral
Dec-19-23 Downgrade Mizuho Buy → Neutral
Mar-17-22 Upgrade UBS Neutral → Buy
Jun-15-21 Initiated BTIG Research Buy
May-21-21 Initiated UBS Neutral
Apr-26-21 Resumed Credit Suisse Outperform
Apr-01-21 Upgrade Mizuho Neutral → Buy
Jan-07-21 Upgrade Guggenheim Neutral → Buy
Nov-24-20 Initiated H.C. Wainwright Buy
Nov-11-20 Initiated Berenberg Buy
Nov-09-20 Initiated Jefferies Buy
Nov-04-20 Initiated Cantor Fitzgerald Overweight
Oct-23-20 Initiated RBC Capital Mkts Outperform
Aug-25-20 Initiated Raymond James Strong Buy
Jul-31-20 Upgrade Robert W. Baird Neutral → Outperform
Jun-25-20 Downgrade Mizuho Buy → Neutral
Jun-25-20 Downgrade Robert W. Baird Outperform → Neutral
Jun-25-20 Downgrade Wells Fargo Overweight → Equal Weight
Dec-03-19 Initiated Cowen Outperform
Dec-03-19 Initiated Goldman Buy
Nov-05-19 Initiated Credit Suisse Outperform
Oct-11-19 Initiated Stifel Buy
Sep-25-19 Initiated Bernstein Outperform
Sep-12-19 Initiated Mizuho Buy
Jul-30-19 Downgrade Guggenheim Buy → Neutral
Jul-08-19 Reiterated Cantor Fitzgerald Overweight
Apr-12-19 Initiated Piper Jaffray Overweight
Mar-29-19 Initiated Robert W. Baird Outperform
View All

Uniqure N V Stock (QURE) Latest News

pulisher
03:59 AM

Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval - insights.citeline.com

03:59 AM
pulisher
Mar 26, 2025

Learn to Evaluate (QURE) using the Charts - Stock Traders Daily

Mar 26, 2025
pulisher
Mar 25, 2025

Stock Watch: Are Gene Therapy Prices Too High For Success? - insights.citeline.com

Mar 25, 2025
pulisher
Mar 16, 2025

(QURE) Trading Report - Stock Traders Daily

Mar 16, 2025
pulisher
Mar 13, 2025

uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World

Mar 13, 2025
pulisher
Mar 09, 2025

Oppenheimer & Co. Inc. Buys New Stake in uniQure (NASDAQ:QURE) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

FY2025 Earnings Estimate for uniQure Issued By HC Wainwright - Defense World

Mar 08, 2025
pulisher
Mar 06, 2025

uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

uniQure CFO Christian Klemt sells $107,407 in shares By Investing.com - Investing.com Australia

Mar 06, 2025
pulisher
Mar 05, 2025

uniQure Reports 2024 Financial Results and Progress - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure’s chief medical officer sells shares worth $13,891 - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure CFO Christian Klemt sells $107,407 in shares - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure’s chief medical officer sells shares worth $13,891 By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure CEO Matthew Kapusta sells shares worth $291,628 By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure chief legal officer sells shares for $72,812 By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure CEO Matthew Kapusta sells shares worth $291,628 - Investing.com

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure chief legal officer sells shares for $72,812 - Investing.com

Mar 05, 2025
pulisher
Mar 04, 2025

uniQure (NASDAQ:QURE) Stock Price Down 7.3% Following Analyst Downgrade - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Wells Fargo & Company Cuts uniQure (NASDAQ:QURE) Price Target to $30.00 - Defense World

Mar 03, 2025
pulisher
Mar 03, 2025

What is William Blair’s Forecast for uniQure Q1 Earnings? - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Don't Ignore The Insider Selling In uniQure - Simply Wall St

Mar 02, 2025
pulisher
Mar 02, 2025

Q1 Earnings Estimate for uniQure Issued By William Blair - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

uniQure Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

Mar 01, 2025
pulisher
Feb 28, 2025

Insider Selling: uniQure (NASDAQ:QURE) CEO Sells 26,727 Shares of Stock - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta Sells 6,717 Shares - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 14,341 Shares - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 2,916 Shares - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Misses Expectations By $0.90 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

uniQure (NASDAQ:QURE) Shares Down 9.5%Should You Sell? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

uniQure (NASDAQ:QURE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

uniQure (NASDAQ:QURE) Given Average Rating of “Buy” by Brokerages - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Uniqure NV earnings missed by $0.82, revenue fell short of estimates - Investing.com Australia

Feb 28, 2025
pulisher
Feb 27, 2025

uniQure CEO Matthew Kapusta sells over $360,000 in stock By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 27, 2025

uniQure CEO Matthew Kapusta sells over $360,000 in stock - Investing.com India

Feb 27, 2025
pulisher
Feb 27, 2025

uniQure CFO Christian Klemt sells shares worth over $186,000 By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 27, 2025

uniQure CFO Christian Klemt sells shares worth over $186,000 - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

Uniqure NV reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

uniQure N.V. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Feb 27, 2025
pulisher
Feb 27, 2025

uniQure Reports 2024 Financial Results and Company Progress - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

uniQure N.V. Reports Progress with AMT-130 for Huntington’s Disease and Updates on Clinical Trials Across its Gene Therapy Pipeline - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire

Feb 27, 2025
pulisher
Feb 26, 2025

uniQure N.V.: A Potential Huntington's Play - Seeking Alpha

Feb 26, 2025
pulisher
Feb 25, 2025

uniQure (QURE) Expected to Announce Earnings on Wednesday - Defense World

Feb 25, 2025
pulisher
Feb 23, 2025

(QURE) Technical Data - Stock Traders Daily

Feb 23, 2025
pulisher
Feb 21, 2025

Huntington's Disease Market Growth to Accelerate in Forecast - openPR

Feb 21, 2025
pulisher
Feb 20, 2025

Pfizer nixes Roche-partnered hemophilia drug (PFE:NYSE) - Seeking Alpha

Feb 20, 2025
pulisher
Feb 20, 2025

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons - Seeking Alpha

Feb 20, 2025
pulisher
Feb 20, 2025

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66% - Yahoo Finance

Feb 20, 2025
pulisher
Feb 19, 2025

24,749 Shares in uniQure (NASDAQ:QURE) Acquired by Palumbo Wealth Management LLC - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

uniQure (NASDAQ:QURE) Stock Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat

Feb 19, 2025

Uniqure N V Stock (QURE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):